Retraction notice to "A role for plasma transforming growth factor-β and matrix metalloproteinases in aortic aneurysm surveillance in Marfan syndrome?" [Atherosclerosis 209(1) (2010) 211-214] DOI: 10.1016/j.atherosclerosis.2009.08.003;A role for plasma transforming growth factor-β and matrix metalloproteinases in aortic aneurysm surveillance in Marfan syndrome?

Atherosclerosis

Volumn 209, Issue 1, 2010, Pages 211-214

  Ahimastos, Anna A ^a   Aggarwal, Anuradha ^b   Savarirayan, Ravi ^c   Dart, Anthony M ^a   Kingwell, Bronwyn A ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin converting enzyme inhibitor; Marfan syndrome; Transforming growth factor

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GELATINASE A; PERINDOPRIL; PLACEBO; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGE DISTRIBUTION; AORTA ANEURYSM; AORTA ROOT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; LONGITUDINAL STUDY; MARFAN SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 77049118487     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.01.027     Document Type: Erratum

References (25)

1. Judge D.P., and Dietz H.C. Marfan's syndrome. Lancet 366 (2005) 1965-1976
2. Dietz H.C., Loeys B., Carta L., et al. Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet 139C (2005) 4-9
3. Keane M.G., and Pyeritz R.E. Medical management of Marfan syndrome. Circulation 117 (2008) 2802-2813
4. Jeremy R.W., Huang H., Hwa J., et al. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol 74 (1994) 369-373
5. Ahimastos A.A., Aggarwal A., D'Orsa K.M., et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA 298 (2007) 1539-1547
6. Wojakowski W., Gminski J., Siemianowicz K., et al. The influence of angiotensin-converting enzyme inhibitors on the aorta elastin metabolism in diet-induced hypercholesterolaemia in rabbits. J Renin Angiotensin Aldosterone Syst 2 (2001) 37-42
7. Ikonomidis J.S., Jones J.A., Barbour J.R., et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation 114 (2006) I365-I370
8. Nataatmadja M., West M., West J., et al. Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 108 Suppl. 1 (2003) II329-II334
9. Roman M.J., Devereux R.B., Kramer-Fox R., et al. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 64 (1989) 507-512
10. Perry G.J., Helmcke F., Nanda N.C., et al. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol 9 (1987) 952-959
11. Levine R.A., Stathogiannis E., Newell J.B., et al. Reconsideration of echocardiographic standards for mitral valve prolapse: lack of association between leaflet displacement isolated to the apical four chamber view and independent echocardiographic evidence of abnormality. J Am Coll Cardiol 11 (1988) 1010-1019
12. Matt P., Habashi J., Carrel T., et al. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?. J Thorac Cardiovasc Surg 135 (2008) 389-394
13. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3 (2003) 422-433
14. Chaudhry F., Cain S.A., Morgan A., et al. Fibrillin-1 regulates the bioavailability of TGF-B. J Cell Biol 176 (2007) 355-367
15. Isogai Z., Ono R.N., Ushiro S., et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 278 (2003) 2750-2757
16. ten Dijke P., and Arthur H.M. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 8 (2007) 857-869
17. Neptune E.R., Frischmeyer P.A., Arking D.E., et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33 (2003) 407-411
18. Palombo D., Maione M., Cifiello B.I., et al. Matrix metalloproteinases. Their role in degenerative chronic diseases of abdominal aorta. J Cardiovasc Surg (Torino) 40 (1999) 257-260
19. Segura A.M., Luna R.E., Horiba K., et al. Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation 98 (1998) II331-II337 [discussion II7-8]
20. Xiong W., Knispel R.A., Dietz H.C., et al. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J Vasc Surg 47 (2008) 166-172 [discussion 72]
21. Karlsson L., Bergqvist D., Lindback J., et al. Expansion of small-diameter abdominal aortic aneurysms is not reflected by the release of inflammatory mediators IL-6, MMP-9 and CRP in plasma. Eur J Vasc Endovasc Surg 37 (2009) 420-424
22. Nagashima H., Sakomura Y., Aoka Y., et al. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation 104 (2001) I282-I287
23. Habashi J.P., Judge D.P., Holm T.M., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312 (2006) 117-121
24. Nagashima H., Uto K., Sakomura Y., et al. An angiotensin-converting enzyme inhibitor, not an angiotensin II type-1 receptor blocker, prevents beta-aminopropionitrile monofumarate-induced aortic dissection in rats. J Vasc Surg 36 (2002) 818-823
25. Loeys B.L., Schwarze U., Holm T., et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 355 (2006) 788-798